Association between public media and trends in new acute coronary syndrome presentations during the first COVID-19 wave in the Netherlands

L. Derks · H. N. Sturkenboom · M. Zaal · S. Houterman · P. Woudstra · R. A. Tio · H. P. A. van Veghel

Accepted: 13 July 2021 / Published online: 29 July 2021
© The Author(s) 2021

Abstract

Background We aimed to evaluate the association between public media and trends in new presentations of acute coronary syndrome (ACS) during the first wave of the coronavirus disease 2019 (COVID-19) in the Netherlands.

Methods New ACS presentations per week in 73 hospitals during the first half of 2019 and 2020 were retrieved from the national organisation Dutch Hospital Data and incidence rates were calculated. Stratified analyses were performed by region, type of ACS and patient characteristics.

Results After the first confirmed COVID-19 case and during lockdown, numbers declined by up to 41% (95% confidence interval (CI): 36–47%) compared to 2019. This reduction was more pronounced for non-ST-segment elevation myocardial infarction (NSTEMI) (48%; 95% CI: 39–55%) and unstable angina (UA; 50%; 95% CI: 40–59%) than for STEMI (34%; 95% CI: 23–43%). There was no association between ACS and COVID-19 incidence rate per region. After the steep decline, a public campaign encouraged patients not to postpone hospital visits. Numbers then increased, without a rebound effect. Trends were similar irrespective of sex, age or socio-economic status. During the outbreak, compared to coronary artery bypass graft procedures, relatively more (acute) percutaneous coronary interventions for NSTEMI and UA were performed.

Conclusion New ACS presentations decreased by up to 41%. Lockdown measures and public campaigns, rather than COVID-19 incidence, were associated with significant changes in new ACS presentations. Even though causality cannot be established, this emphasises the role of the public media and healthcare organisations in informing patients to prevent underdiagnoses of ACS and associated health damage.

Keywords Acute coronary syndrome · COVID-19 · Non-ST-segment elevation myocardial infarction · ST-segment elevation myocardial infarction · Unstable angina

Introduction

The coronavirus disease 2019 (COVID-19) pandemic is a major burden affecting healthcare worldwide. After the first official case of COVID-19 in the Netherlands was reported on 27 February 2020 [1], numbers rose exponentially [2]. Compulsory measures and social distancing interventions in order to prevent further transmission were taken by the Dutch government and announced in the public media. Downregulation of regular healthcare to acute care only was inevitable due to the increase in hospitalisations of COVID-19 patients.
In several countries, a decline in presentations of acute coronary syndrome (ACS) was observed [3–14]. In cases of ST-segment elevation myocardial infarction (STEMI), timely revascularisation is warranted in order to prevent heart failure, mechanical complications, cardiogenic shock and even early death, and treatment delay is an independent negative predictor of survival [15–17]. Consequently, identifying and understanding the trends, scale, nature of and explanations for changes in new ACS presentations is of utmost importance, in order to prevent avoidable cardiovascular complications during comparable crisis situations.

The aim of the present study was to evaluate trends in new presentations and in-hospital treatment for ACS during the first wave of the COVID-19 pandemic in the Netherlands, and to investigate the association thereof with COVID-19 incidence rate, national governmental countermeasures and recommendations by the Netherlands Society of Cardiology (NVVC) announced in the public media.

Methods

In-hospital healthcare activities, related diagnoses and patient characteristics are registered by physicians for 73 out of 74 Dutch hospitals in the Dutch National Hospital Care Registration (LBZ) [18]. All patients newly presenting with ACS, from 1 January until 30 June of both 2019 and 2020, were included for analyses on a weekly basis. Presentations were selected based on the following criteria: (1) registered by a cardiologist; (2) diagnosis of STEMI, non-STEMI (NSTEMI) or unstable angina (UA); (3) it concerns an initial presentation; and (4) the patient had no similar diagnosis in the 2 years preceding this study’s period of interest (2019 and 2020). Patient and hospital privacy was assured by aggregating data into seven regions, containing at least three hospitals, by a delegate of Dutch Hospital Data, the organisation that administers LBZ data [18, 19].

Data were divided into groups by (1) diagnoses (STEMI, NSTEMI, UA), (2) age (< 60, 60–79, ≥ 80 years), (3) sex, (4) socio-economic status (SES), constructed using postal codes following the methods described by Statistics Netherlands (CBS) [20], and (5) geographical region. Percutaneous coronary intervention (PCI) and coronary artery bypass graft (CABG) as in-hospital treatment for ACS were categorised as acute or non-acute, based on payment title codes assigned at the discretion of the physician (Electronic Supplementary Material, Table S1).

The number of confirmed COVID-19 cases per region was extracted from the data of the National Institute for Public Health and the Environment [2, 21]. Together with the 1 January 2020 provisional population numbers for each geographical region, which were retrieved from the CBS, the incidence rate of COVID-19-positive cases per week, per region, per 100,000 inhabitants was determined [21, 22]. Information and timing of stepwise lockdown measures introduced by the Dutch government were obtained online (Electronic Supplementary Material, Table S2) [23].

Statistical analysis

The number of ACS presentations and procedures (acute and non-acute PCI and CABG) performed per week were presented as counts. The percentage change per week was calculated using the equivalent week of 2019 as a reference. Differences between 2019 and 2020 were analysed using a Poisson distribution, to calculate 95% confidence intervals (95% CI). To determine statistically significant changes per week for distinct group of ACS presentations, percentages were compared using omnibus chi-square tests. P-values < 0.05 were considered statistically significant.

Results

Complete data concerning new ACS presentations and the procedures performed were available for 73 hospitals. The number of ACS presentations and the incidence rate of COVID-19 cases per week are presented in Fig. 1. Fig. 2 presents numbers of STEMI, NSTEMI and UA presentations, together with public announcements of countermeasures and healthcare campaigns during the COVID-19 outbreak. Before the onset of the COVID-19 outbreak in week 9 of 2020, no significant differences in new presentations were observed as compared to 2019. After the report of the first confirmed COVID-19 case in week 9, a significant decline was observed with a maximal decrease in presentations of 41% (95% CI: 36–47%) by week 13. The maximal reductions for NSTEMI (48%; 95% CI: 39–55%) and UA (50%; 95% CI: 40–59%) were comparable. The maximal decline in new STEMI presentations was 34% (95% CI: 23–43%) in week 14.

In parallel to the decline in presentations an increase in confirmed COVID-19 cases was observed. On 23 March (week 13) a nationwide lockdown was
initiated. On 27 March (week 13), healthcare providers made a public call to all patients with serious complaints not to postpone hospital visits, followed by a second call to all patients with cardiac complaints made by the NVVC, on 1 April (week 14). Thereafter a gradual increase in presentations for STEMI and NSTEMI was observed, to levels comparable to the pre-COVID-19 period by week 23. For UA, a significant reduction was observed up to week 23 (16%; 95% CI: 3–27%). No significant rebound in new ACS presentations was observed. The first decrease in newly confirmed COVID-19 cases was registered in week 16.
Table 1  Percentage difference (2019 vs 2020) in new presentations of acute coronary syndrome per week, stratified by region and patient characteristics

| Week | Geographical location  | A | B | C | D | E | F | Geographical location a (mean incidence of confirmed COVID-19 cases per week per 100,000) | G |
|------|-----------------------|---|---|---|---|---|---|-------------------------------------|---|
| 9    | 2%                    | -19% b | -34% b | 15% | -3% | -11% | 25% | 36.5 | -22% |
| 10   | -10%                  | -28% b | -34% b | 26% | -23% b | -6% | 3% | 3% | -10% |
| 11   | -35% b                | -21% b | -46% b | -44% b | -41% b | -21% b | -7% | -4% | -14% b |
| 12   | -28% b                | -40% b | -39% b | -53% b | -41% b | -40% b | -6% | -15% b | -35% b |
| 13   | -21% b                | -41% b | -38% b | -41% b | -22% b | -40% b | -13% | -20% b | -40% b |
| 14   | -20% b                | -45% b | -26% b | -48% b | -26% b | -40% b | -46% b | -45% b | -33% b |

Table 2  Percentage difference (2019 vs 2020) in in-hospital treatment for new presentations of acute coronary syndrome per week

| Week | Acute PCI | Non-acute PCI | CABG | Acute PCI | Non-acute PCI | CABG | Acute PCI | Non-acute PCI | CABG |
|------|-----------|---------------|------|-----------|---------------|------|-----------|---------------|------|
| 9    | -6% a     | -3%           | -9%  | -2%       | -16%          | -4%  | -2%       | -14%          | 3%   |
| 10   | 16%       | 31%           | -50% a | 11%       | -14%          | -21% | 11%       | -16%          | -16% |
| 11   | 0%        | -8%           | -57% a | 0%        | -3%           | -16% | 0%        | -15%          | -12% |
| 12   | -14%      | -48% a        | -39% a | -8%       | -32%          | -46% b | -21%      | -62% a        | -62% |
| 13   | -21% a    | -39% a        | -44% a | -37%      | -32%          | -46% a | -39% a    | -49% a        | -49% a|
| 14   | -37% a    | -48% a        | -33% a | -36%      | -29%          | -33% a | -29% a    | -30% a        | -30% a|

Table 2  Percentage difference (2019 vs 2020) in in-hospital treatment for new presentations of acute coronary syndrome per week

| Week | STEMI | Acute PCI | Non-acute PCI | CABG | NSTEMI | Acute PCI | Non-acute PCI | CABG | UA | Acute PCI | Non-acute PCI | CABG |
|------|-------|-----------|---------------|------|--------|-----------|---------------|------|----|-----------|---------------|------|
| 9    |       | -6% a     | -29%          | -19% | -2%    | -30%      | -3%           | 3%   | -13% | -11%      | -12%          | 3%   |
| 10   |       | 16%       | 31%           | -50% a | 11%    | -14%      | -21%          | -4%  | -11% | -26%      | -51%          | -2%  |
| 11   |       | 0%        | -8%           | -57% a | 0%     | -3%       | -16%          | -2%  | -11% | -7%       | -12%          | 7%   |
| 12   |       | -14%      | -31% a        | -39% a | -8%    | -15%      | -45% a        | -62% a| -2%  | -12%      | -48% a        | -7%  |
| 13   |       | -21% a    | -49% a        | -44% a | -37%   | -62% a    | -62% a        | -64% a| -13% | -12%      | -44% a        | -81% a|

From week 20 onwards, alleviation of countermeasures was initiated. After the initiation or alleviation of different lockdown measures no significant changes in new ACS presentations were observed when compared to the previous week. Therefore, no association between the initiation or alleviation of lockdown measures and new ACS presentations could be established.

During the COVID-19 outbreak, no significant differences were observed in the reduction in new ACS presentations among the sexes (p-values = 0.41–0.83), SES (p-values = 0.06–0.99) or different age groups (p-values = 0.14–0.96). The decrease was more pronounced in region G (58%), in week 14, and lowest in region A (35%), in week 13. Although the incidence rate of COVID-19 was higher in region G, a similar reduction was observed in region C, where the incidence rate was relatively low (Tab. 1). Omnibus chi-square tests showed no significant differences among regions in the decline in the number of new ACS presentations per week during weeks 9 through 14 (p-values = 0.07–0.87).

In parallel with the reduction in STEMI presentations (34%) in week 14, a similar decrease in acute PCI (37%; 95% CI: 26–47%), non-acute PCI (38%; 95% CI: 14–57%) and CABG (44%; 95% CI: 30–82%) procedures for STEMI was observed. In week 13, the reduction in NSTEMI presentations (48%) was not accompanied by a similar decrease in acute PCI procedures (29%; 95% CI: 13–43%), while the reductions in non-acute PCI (62%; 95% CI: 46–74%) and CABG (62%; 95% CI: 37–78%) procedures were more in line...
with the expected. No significant decrease in acute PCI procedures for UA was observed, even though UA presentations declined by up to 50% in week 13. There were, however, significant reductions in non-acute PCI and CABG procedures for UA. The decrease in CABG procedures (74%; 95% CI: 50–88%) were more than expected in relation to the maximum reduction in UA presentations. In conclusion, proportionally more acute PCI procedures for NSTEMI and more PCI (acute and non-acute) procedures for UA were observed during the outbreak as compared to 2019 (Tab. 2).

**Discussion**

In the present study, a significant reduction in new ACS presentations of up to 41% was observed during the COVID-19 pandemic as compared to the equivalent period in 2019. The decrease was more pronounced for NSTEMI and UA than for STEMI, in accordance with observations in Italy (54% vs 26%), England (49% vs 29%) and Austria (53% vs 31%) [4, 7, 24]. Despite the high incidence of COVID-19, an increase in ACS presentations was observed from week 14 onwards.

The first significant decrease in new ACS presentations was observed in the week after the first confirmed case of COVID-19 and before national countermeasures were announced. Communication about the first COVID-19 case and reports of rapidly increasing numbers of COVID-19-positive cases clearly preceded the change in medical help-seeking behaviour. There are several potential explanations for the observed decrease in new ACS presentations. Fear of contracting COVID-19 might have caused patients to postpone hospital visits as described previously, whilst decreased physical activities or diminished stress during the lockdown could have contributed to the occurrence of fewer ACS cases [3, 25, 26]. The simultaneous reduction in air pollution from week 9 onwards reflects a sudden decrease in road transport (and economical) activities [27]. Furthermore, the reduction in air pollution in itself might have contributed to the decrease in ACS, since it is a known trigger for myocardial infarction [13]. Lastly, patients who normally developed ACS potentially developed severe COVID-19 disease; in such cases, cardiac complaints might have gone undetected or people may have died from the disease before developing ACS. However, these potential contributing factors do not fully explain the observed trend in presentations during the COVID-19 pandemic in the Netherlands.

In our study an increase in ACS presentations was observed following public calls by healthcare professionals in week 13. This effect was also described after a public call by the British Heart Foundation and a British Cardiovascular Society publicity campaign [3]. In the United States and New Zealand the aforementioned association was less explicitly described [28–30]. The reduction in presentations and the increase after the public calls to patients might be explained by the effect of the public media on patients’ behaviour. According to Wallack et al. (public) media can be used to achieve ‘advocacy’, to create a shift in public opinion, which can be useful in health-promotion campaigns [31]. Renaud et al. provided a conceptual framework of how the media can shape socially constructed understandings of health [32]. In this framework of health-promotion interventions, in order to achieve advocacy, initiation of changes in health-related norms determined by the public (‘receivers’) must be promoted by agents (i.e. healthcare specialists) involved in the changing process. During the COVID-19 outbreak, public health messages promoted by healthcare specialists and governmental delegates, together with updates on epidemiological facts, death rates, and national countermeasures aimed at containing the virus, might have caused a shift in public ‘norms’ towards general fearfulness, resulting in patients avoiding social interactions and postponing hospital visits. The subsequent public calls by healthcare specialists may have helped to overcome the fear of infection. Thus, medical professionals play a public role in achieving ‘advocacy’ and are thus pivotal in preventing unwanted help-seeking delays during unprecedented events, such as the COVID-19 pandemic.

The likelihood of an effect of public media on patients’ behaviour, and thus the observed trends, is further supported by similar changes in ACS presentations per patient group and among regions, even though incidence rates of COVID-19 varied per region. This observation was confirmed in Italy and France, which had no regional differences in ACS presentations, while large differences in incidence rates were seen between the northern and southern parts of the respective countries [7, 12]. Accompanied by the decrease in new ACS presentations, we also observed a relative increase in acute PCIs for NSTEMI and PCIs for UA, which was most likely the result of downregulation of regular healthcare, with postponement of elective procedures, resulting in better availability catheterisations staff and facilities. Furthermore, the large numbers of COVID-19 patients caused capacity problems for operation facilities and intensive care units for postoperative care, making CABG a less favourable treatment option. More research regarding treatment prevalence and long-term outcomes of ACS during the COVID-19 pandemic is therefore warranted.

Finally, no rebound in the number of new ACS presentations was observed after the initial decline and/or after termination of the lockdown measures. Potentially, the reduction in new ACS presentations reflects underdiagnoses of true cases. This was further substantiated by an observed increase in out-of-hospital cardiac arrest during the COVID-19 pandemic [33, 34]. More awareness concerning possible
missed ACS cases and consequently new-onset heart failure and mortality during and after the pandemic is warranted. We therefore suggest prospective research concerning new-onset heart failure. Also, in order to identify the need for an intervention at an early stage, we suggest that national data on ACS admissions should be tracked in a timely fashion and made available to public health agencies. We emphasise the impact of public media and the pivotal role played by medical professionals in preventing unwanted delays in help-seeking during the ongoing pandemic or comparable unprecedented events.

When interpreting our findings, some limitations should be noted. First, for this study, data of the LBZ, provided by healthcare providers rather than a clinical register, were used. However, previous research showed a high level of comparison between LBZ data and clinical registration of ACS patients [35]. Furthermore, with almost complete national coverage, and by comparing 2020 data with 2019 data, we consider that the presented numbers are reliable. Secondly, only a few stratifications could be made to identify potentially vulnerable groups. Finally, it was not possible to investigate the potential impact on outcomes by using the current data or to deduct causality between the observed and described associations.

In conclusion, a significant reduction in new ACS presentations was observed during the COVID-19 pandemic. The reduction was more pronounced for UA and NSTEMI than for STEMI. Under-diagnosis of ACS, the postponement of hospital visits and the effect of the public media on patients’ behaviour are the most likely explanatory factors for the observed changes in new ACS presentations. Although causality cannot be established, additional awareness regarding the possible effect of communication by (societies of) healthcare providers and public media on new ACS presentations during the ongoing pandemic or comparable unprecedented events is warranted.

Conflict of interest L. Derks, H.N. Sturkenboom, M. Zaal, S. Houterman, P. Woudstra, R.A. Tio and H.P.A. van Veghel declare that they have no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Ministry of Health, Welfare and Sport. Letter to Speaker of the House of Representatives concerning the first COVID-19 patient of the Netherlands. https://www.rijksoverheid.nl/documenten/kamerstukken/2020/02/27/kamerbrief-eerste-covid-19-patient-in-nederland. Accessioned 6 Oct 2020, in Dutch.

2. National Institute for Public Health and the Environment (RIVM). Regional differences in the coronavirus epidemic. https://www.rivm.nl/en/news/regional-differences-in-coronavirus-epidemic. Accessed 6 Oct 2020.

3. Maffham MM, Spata E, Goldacre R, et al. COVID-19 pandemic and admission rates for and management of acute coronary syndromes in England. Lancet. 2020;396:381–9.

4. Metzler B, Siostrzonek P, Binder RK, et al. Decline of acute coronary syndrome admissions in Austria since the outbreak of COVID-19: the pandemic response causes cardiac collateral damage. Eur Heart J. 2020;41:1852–3.

5. Abdelaziz HK, Abdelrahman A, Nabi A, et al. Impact of COVID-19 pandemic on patients with ST-segment elevation myocardial infarction: insights from a British cardiac center. Am Heart J. 2020;226:45–8.

6. Tsoufis K, Chrysohoou C, Kariori M, et al. The mystery of “missing” visits in an emergency cardiology department, in the era of COVID-19: a time-series analysis in a tertiary Greek General Hospital. Clin Res Cardiol. 2020;1:7.

7. Rosa SD, Spaccarotella C, Basso C, et al. Reduction of hospitalisations for myocardial infarction in Italy in the COVID-19 era. Eur Heart J. 2020;41:2083–8.

8. Huet F, Prieur C, Schurtz G, et al. One train may carry another: acute cardiovascular diseases could be neglected because of the COVID-19 pandemic. Arch Cardiovasc Dis. 2020;113:303–7.

9. De Filippo O, D’Ascenzo F, Angelini I, et al. Reduced rate of hospital admissions for ACS during Covid-19 outbreak in Northern Italy. N Engl J Med. 2020;383:88–9.

10. Rodriguez-Leor O, Cid-Alvarez B, Ojeda S, et al. Impact of the COVID-19 pandemic on interventional cardiology activity in Spain. RECInterv Cardiol. 2020;2:82–9.

11. Garcia S, Albaghdadi MS, Meraj PM, et al. Reduction in ST-segment elevation cardiac catheterization laboratory activations in the United States during COVID-19 pandemic. J Am Coll Cardiol. 2020;75:2871–2.

12. Mesnier J, Cottin Y, Coste P, et al. Hospital admissions for acute myocardial infarction before and after lockdown according to regional prevalence of COVID-19 and patient profile. Lancet Public Health. 2020;5:e336–42.

13. Claeyis MJ, Rajagopalan S, Nawrot TS, et al. Climate and environmental triggers of acute myocardial infarction. Eur Heart J. 2017;38:955–60.

14. Bollmann A, Pellissier Y, Hohenstein S, et al. Cumulative hospitalization deficit for cardiovascular disorders in Germany during the COVID-19 pandemic: insights from the German-wide Helios hospital network. Eur Heart J Qual Care Clin Outcomes. 2020; https://doi.org/10.1093/ehjqcco/qcaa071.

15. White HD, Chew DP. Acute myocardial infarction. Lancet. 2008;372:570–84.

16. Scholz KH, Maier SKG, Maier LS, et al. Impact of treatment delay on mortality in ST-segment elevation myocardial infarction (STEMI) patients presenting with and without haemodynamic instability: results from the German prospective, multicentre FITT-STEMI trial. Eur Heart J. 2018;39:1065–74.

17. Wijns W, Naber CK. Reperfusion delay in patients with high-risk ST-segment elevation myocardial infarction: every
minute counts, much more than suspected. Eur Heart J. 2018;39:1075–7.
18. Landelijke Basisregistratie Ziekenhuiszorg (LBZ). https://www.dhd.nl/producten-diensten/lbz/Paginas/dataverzameling-lbz.aspx. Accessed 7 Oct 2020, in Dutch.
19. Dutch Hospital Data (DHD). Protocol use of DHD data collections by third parties. https://www.dhd.nl/producten-diensten/gegevensverzoek/documents/DHD%20Gegevensprotocol%20versie%202.2.pdf. Accessed 7 Oct 2020, in Dutch.
20. Statistics Netherlands (CBS). The hospital standardised mortality ratios (HSMR) 2018 methodological report, table classification of variables. https://www.cbs.nl/en-gb/our-services/methods/surveys/aaavnellende-onderzoeksbeschrijvingen/hsmr-2018-methodological-report. Accessed 10 Oct 2020.
21. National Institute for Public Health and the Environment (RIVM). COVID-19 dataset. https://data.rivm.nl/covid-19. Accessed 21 Sept 2020.
22. Statistics Netherlands (CBS). Provisional population numbers, 1-1-2020. https://www.cbs.nl/nl-nl/maatwerk/2020/11/voorlopige-bevolkingsaantallen-1-1-2020. Accessed 6 Oct 2020, in Dutch.
23. Government of the Netherlands. Government of the Netherlands. https://www.government.nl/. Accessed 6 Oct 2020.
24. Wu J, Mamas M, Rashid M, et al. Patient response, treatments, and mortality for acute myocardial infarction during the COVID-19 pandemic. Eur Heart J Qual Care Clin Outcomes. 2020;https://doi.org/10.1093/ehjqcco/qcaa062.
25. C-CFT, Cheung K-S, Lam S, et al. Impact of coronavirus disease 2019 (COVID-19) outbreak on ST-segment—Elevation myocardial infarction care in Hong Kong, China. Circ Cardiovasc Qual Outcomes. 2020;13:e6631.
26. Maugeri G, Castrogiovanni P, Battaglia G, et al. The impact of physical activity on psychological health during Covid-19 pandemic in Italy. Heliyon. 2020;6:e04315.
27. European Environment Agency. Air quality and COVID-19. https://www.eea.europa.eu/themes/air/air-quality-and-covid19. Accessed 3 Nov 2020.
28. Gluckman TJ, Wilson MA, Chiu S-T, et al. Case rates, treatment approaches, and outcomes in acute myocardial infarction during the coronavirus disease 2019 pandemic. JAMA Cardiol. 2020;5:1419.
29. Chan DZL, Stewart RAH, Kerr AJ, et al. The impact of a national COVID-19 lockdown on acute coronary syndrome hospitalisations in New Zealand (ANZACS-QI 55). Lancet Reg Health West Pac. 2020;5:100056.
30. Ministry of Health. COVID-19 media update, 6 April. https://www.health.govt.nz/news-media/news-items/covid-19-media-update-6-april. Accessed 5 April 2021.
31. Wallow L, Dorfman L, Jernigan D, et al. Media advocacy and public health. London: SAGE; 1993.
32. Renaud L, Bouchard C, Caron-Bouchard M, et al. A model of mechanisms underlying the influence of media on health behaviour norms. Can J Public Health. 2006;97:149–52.
33. Baldi E, Sechi GM, Mare C, et al. Out-of-hospital cardiac arrest during the Covid-19 outbreak in Italy. N Engl J Med. 2020;383:496–8.
34. Marijon E, Karam N, Jost D, et al. Out-of-hospital cardiac arrest during the COVID-19 pandemic in Paris, France: a population-based, observational study. Lancet Public Health. 2020;5:e437–e43.
35. Eindhoven DC, van Staveren LN, van Erkelens JA, et al. Nationwide claims data validated for quality assessments in acute myocardial infarction in the Netherlands. Neth Heart J. 2018;26:13–20.